Ask AI
Early-Stage TNBC

CE / CME

Evolving Treatment Landscape for Early-Stage TNBC With and Without gBRCAm

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: June 26, 2026

Expiration: December 25, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
  2. National Cancer Institute. Cancer stat facts: female breast cancer subtypes. seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed June 18, 2026
  3. Dietze EC, Sistrunk C, Miranda-Carboni G, et al. Triple-negative breast cancer in African-American women: disparities versus biology. Am J Pathol. 2018;188:280-290.
  4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948.
  5. Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27:8-16.
  6. Asad S, Barcenas CH, Bleicher RJ, et al. Sociodemographic factors and breast cancer subtype. J Natl Compr Canc Netw. 2021;19:797-805.
  7. Prakash O, Hossain F, Danos D, et al. Racial disparities in triple-negative breast cancer. Front Public Health. 2020;8:576964.
  8. Silber JH, Rosenbaum PR, Ross RN, et al. Disparities in breast cancer survival by socioeconomic and racial factors. Milbank Q. 2018;96:706-754.
  9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.2.2026. nccn.org. Accessed June 18, 2026.
  10. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.
  11. Sharma P. Biology and management of patients with triple-negative breast cancer. Oncologist. 2016;21:1050-1062.
  12. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from CIMBA. Cancer Epidemiol Biomarkers Prev. 2012;21:134-147.
  13. O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, et al. BRCA mutation prevalence and clinical implications in breast cancer. Breast Cancer Res. 2020;22:114.
  14. Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in breast cancer. Cancer. 2012;118:2787-2792.
  15. Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10:227-235.
  16. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222-2233.
  17. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate. v.3.2026. nccn.org. Accessed June 18, 2026.
  18. Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  19. Capecitabine [prescribing information]. Greifswald, Germany: CHEPLAPHARM Arzneimittel GmbH; 2026.
  20. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
  21. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
  22. Rose M, Burgess JT, O'Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.
  23. Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018;124:2498-2506.
  24. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  25. Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981-1991.
  26. Schmid P, Cortes J, Dent R, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage triple-negative breast cancer: final analysis from the phase 3 KEYNOTE-522 study. J Clin Oncol. 2026;44(suppl 16):507.
  27. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  28. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
  29. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-e28.
  30. Hurvitz SA, Gonçalves A, Rugo HS, et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial. Oncologist. 2020;25:e439-e450.
  31. Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38:3468-3493.
  32. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis. v.1.2026. Accessed June 18, 2026.
  33. Goldenberg DM, Sharkey RM. Sacituzumab govitecan: design and mechanism of action of a TROP-2-directed antibody-drug conjugate. MAbs. 2019;11:987-995.
  34. Kopp A, Jonat W, Schmaus J, et al. TROP-2-directed antibody-drug conjugates in cancer. Mol Cancer. 2023;22:102.
  35. Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion Study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678-4687.
  36. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  37. Sacituzumab govitecan-hziy [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2025.
  38. Datopotamab deruxtecan-dlnk [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2026.
  39. Tolaney SM, DeMichele A, Takano T, et al. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab +/- capecitabine for residual triple-negative breast cancer. Future Oncol. 2024;20:1479-1489.
  40. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med. 2026;394:354-366.
  41. Bardia A, Pusztai L, Albain KS, et al. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan +/- durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024;16:17588359241248336.
  42. McArthur HL, Tolaney SM, Dent R, et al. TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naive early-stage triple-negative or HR-low/HER2-negative breast cancer. Ther Adv Med Oncol. 2025;17:17588359251313614.
  43. Fleming PJ Jr, Karpio S, Lombardo N. Sacituzumab govitecan for treatment of refractory triple-negative metastatic breast cancer. J Adv Pract Oncol. 2021;12:747-752.
  44. Rugo HS, Tolaney SM, Loirat D, et al. Safety management of sacituzumab govitecan. NPJ Breast Cancer. 2022;8:98.
  45. Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan toxicity management in breast cancer. Oncologist. 2021;26:827-834.
  46. Rugo HS, Bardia A, Bruno DS, et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer. 2025;33:756.
  47. Lu R, Morphey A, Diaz F, et al. Management of ocular toxicity in patients receiving belantamab mafodotin. J Adv Pract Oncol. 2023;14:300-306.
  48. Tarantino P, Tolaney SM, et al. Interstitial lung disease associated with antibody-drug conjugates in breast cancer. JAMA Oncol. 2021;7:1873-1881.